Idorsia

Allschwil, Switzerland

The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients.

$313.9M raised

Jun 2026

Post-IPO Debt

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Idorsia raised?

Idorsia has raised $313.9M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in June 2026.

Who are Idorsia's investors?

Idorsia's investors include CARB-X, Pharmakon Advisors, Jean-Paul Clozel.

Where is Idorsia headquartered?

Idorsia is headquartered in Allschwil, Switzerland.

What does Idorsia do?

The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients.

What stage is Idorsia at?

Idorsia is at the Post-IPO Debt stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated June 9, 2026.

MLA

"Idorsia — Funding & Investors." VCBacked, June 9, 2026, https://www.vcbacked.co/company/idorsia. Accessed July 2, 2026.

APA

VCBacked. (2026). Idorsia — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/idorsia

Wikipedia (cite web)

{{cite web |title=Idorsia — Funding & Investors |url=https://www.vcbacked.co/company/idorsia |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated June 9, 2026.